CAS: 1073-69-4; (4-Chlorophenyl)Hydrazine

相似化合物

1073-70-7 1397232-43-7 19763-90-7

上下游产品

N-chloro-N'-phenyl-ureaN-chloro-N'-phenyl-urea p-chlorobenzenediazonium chloride 4-chloro-aniline p-chlorobenzenediazonium tetrafluoroborate furfural-(4-chloro-phenylhydrazone) 1-(4-chloro-phenyl)-1,2-dihydro-pyridazine-3,6-dione 4-Chlorphenylmaleinhydrazidsaeure N'-(4-chlorophenylpicolino)hydrazide

📜对氯苯胺置于盐酸,Sodium Nitrite,Sodium Sulfite体系中,用 水 用作溶剂,化学反应 6.0H,以70.67%的收率获得4-氯苯肼
参考文献:潜在的c-Met抑制剂4-(2-氟苯氧基)-3,3'-联吡啶衍生物的合成和生物学评估
标题:潜在的c-Met抑制剂4-(2-氟苯氧基)-3,3'-联吡啶衍生物的合成和生物学评估
摘要:通过基于结构的分子杂交方法,设计合成了六种新颖的与氮杂芳基甲酰胺/胺骨架共轭的4-(2-氟苯氧基)-3,3'-联吡啶衍生物.评估了目标化合物在体外对四种癌细胞系(ht-29,A549,Mkn-45和mda-Mb-231)的c-Met激酶抑制活性和细胞毒性.大多数化合物均表现出中等至出色的效力,最有前途的候选蛋白26C(c-Met激酶ic 50 = 8.2 Nm)在体外对c-Met上瘾的mkn-45细胞系的细胞毒性增加了4.7倍(ic 50 = 3 Nm),优于foretinib(ic 50 = 23 Nm).初步的结构-活性关系表明,1 H-苯并[e] [1,3,4]噻二嗪-3-羧酰胺-4,4-二氧化物部分作为连接基有助于抗肿瘤作用.
Doi:10.1016/j.Ejmech.2016.04.062

专利信息

专利号:WO-2018019249-A1
优先权日:2016-07-27
标题 :Process for continuous flow synthesis of 4-chlorophenylhydrazine salt
发明人：MA BING; PAN SHUAI; PU DENGPAN
权利人:SHANGHAI HYBRID-CHEM TECH
摘要:The present invention provides a process for continuous flow synthesis of a 4-chlorophenylhydrazine salt; the three reaction steps of diazotization, reduction, and acidolysis salt formation are organically integrated in an innovative manner; using a 4-chloroaniline acidic stock solution, a diazotization reagent, a reducing agent, and acid as starting materials, continuously performing in sequence the three reaction steps of diazotization, reduction, and acidolysis salt formation to obtain a 4-chlorophenylhydrazine salt; the synthesis process is carried out in an integrated reactor and is an integrated solution. The reaction starting materials are added continuously via the material feed inlet of the integrated reactor; the three reaction steps of diazotization, reduction, and acidolysis salt formation are performed continuously in sequence in the integrated reactor; 4-chlorophenylhydrazine salt is obtained continuously from the material outlet of the integrated reactor; the total reaction time is ≤20 minutes. In comparison with conventional production processes, the total reaction time is greatly shortened and safety is significantly improved; furthermore, neither the reaction process nor the reaction product contain any reaction by-products (such as diazoamino compounds and reduction reaction intermediates); the described continuous flow process does not require an additional purification step and produces a high-purity product having a purity of 99% or higher, while also achieving a maximum yield of 99.5% or higher.

专利号:US-6025492-A
优先权日:1996-08-30
标 题 :Synthesis of a hydrazone β-keto ester by the reaction with a diazo ester
发明人：SHAH AJIT S; CLARK JERRY D; MA YINONG; PETERSON JAMES C; PATELIS LEFTERIS
权利人:MONSANTO CO
摘要:The present invention relates to the synthesis of a hydrazone β-keto ester by the reaction of an alkyl diazoester with a hydrazone aldehyde in the presence of a Lewis acid In a preferred embodiment, the hydrazone β-keto ester is then converted into a pyridazinone compound by the reaction with an alkyl acid chloride in the presence of a base, followed by acidification. A process for the production of a hydrazone aldehyde, which comprises contacting a hydrazine and glyoxal, is also described.

专利号:WO-2020094440-A1
优先权日:2018-11-07
标题 :Process for the synthesis of aryl hydrazines
发明人：WANG JUSTIN; HARTWIG JOHN F; ZUEND STEPHAN; BORATE KAILASKUMAR; SHINDE HARISH; GOETZ ROLAND
权利人:BASF SE
摘要:The invention relates to a process for the synthesis of aryl hydrazinesof formula I or a salt thereof, which process comprises subjecting an arene of formula II to a coupling reaction with hydrazine or a derivative thereof, wherein the coupling reaction is conducted in the presence of a catalyst comprising palladium and a diphosphine ligand, wherein the phosphorus atoms are connected through two, three, four, or five atoms selected from car- bon, nitrogen, oxygen or iron, and in which the non-connecting phosphorus substituents are C 1- C 10- alkyl or C 3 -C 10 -cycloalkyl, wherein the amount of Pd used is up to 0.5 mol-% relative to the amount of arene of formula II; and a base.

专利号:EP-0923540-B1
优先权日:1996-08-30
标题 :Synthesis of a hydrazone beta-keto ester by the reaction with a diazo ester
发明人：SHAH AJIT S; CLARK JERRY D; MA YINONG; PETERSON JAMES C; PATELIS LEFTERIS
权利人:MONSANTO TECHNOLOGY LLC
摘要:The present invention relates to the synthesis of a hydrazone β-keto ester by the reaction of an alkyl diazo ester with a hydrazone aldehyde in the presence of a Lewis acid. In a preferred embodiment, the hydrazone β-keto ester is then converted into a pyridazinone compound by the reaction with an alkyl acid chloride in the presence of a base, followed by acidification. The present invention also relates to a continuous process for the production of a hydrazone aldehyde comprising contacting a hydrazine and glyoxal, wherein the hydrazine and the glyoxal are added simultaneously to a reactor at a controlled rate.

专利号:US-7153960-B2
优先权日:2001-12-10
标 题:Synthesis of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones
发明人：ZHOU JIACHENG; OH LYNETTE M; MA PHILIP; LI HUI-YIN; CONFALONE PASQUALE
权利人:BRISTOL MYERS SQUIBB CO
摘要:A novel process and intermediates thereof for making 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones of the type shown below from appropriate phenyl hydrazines is described. n nThese compounds are useful as factor Xa inhibitors.

专利号:US-4713383-A
优先权日:1984-10-01
标 题:Triazoloquinazoline compounds, and their methods of preparation, pharmaceutical compositions, and uses
发明人：FRANCIS JOHN E; GELOTTE KARL O
权利人:CIBA GEIGY CORP
摘要:[1,2,4]triazolo[1,5-c]quinazoline compounds of the formula wherein R1 is optionally substituted phenyl, pyridyl, furyl thienyl, dihydro or tetrahydro furanyl or thienyl, pyranyl, or 0-ribofuranosyl; R2 is hydrogen or lower alkyl; X is oxygen or NR3, R3 is as defined in the claims, and ring A is unsubstituted or substituted as set forth in the claims. The compounds wherein X is N-R3 are especially useful as adenosine antagonists and for the treatment of asthma. The compounds wherein X is oxygen are useful as benzodiazepine antagonists and as intermediates in the synthesis of the compounds wherein X is N-R3.